U fiirso qoraalka hoose ka dibna ka jawaab su'aasha kadib isla luqadda qoraalka:  Gudbinta: Laga bilaabo 2019, laba iyo toban daawo oo wax ka beddelaya cudur ayaa ay oggolaadeen hay'adaha sharciyeynta ee cudurka sclerosis badan ee soo noqnoqda (RRMS). Waxaa ka mid ah interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, iyo cladribine. Waxtarka kharashkoodu ma cadda ilaa 2012. Bishii Maarso 2017 FDA waxay ansixisay ocrelizumab, oo ah anti-CD20 monoclonal antibody, oo ah daaweyn loogu talagalay RRMS, oo leh shuruudaha dhowr tijaabooyin caafimaad oo wajiga IV ah. RRMS waxay si dhexdhexaad ah waxtar ugu leeyihiin yareynta tirada weerarada. Daawooyinka interferon iyo glatiramer acetate waa daaweynta safka koowaad waana ku dhowaad isku mid, waxay yareeyaan dib u dhaca qiyaastii 30%. Daaweynta mudada dheer ee la bilaabo waqti hore waa mid amaan ah oo wanaajisa natiijooyinka. Natalizumab wuxuu yareeyaa heerka soo noqoshada ka badan daawooyinka safka koowaad; si kastaba ha noqotee, sababo la xiriira arrimaha saameynta xun, waa daawo safka labaad ah oo loogu talagalay dadka aan ka jawaabin daaweynta kale ama cudurka daran. Mitoxantrone, oo isticmaalkeeda ay xadeynayaan dhibaatooyinka daran ee soo raaca, waa ikhtiyaarka saddexaad ee loogu talagalay dadka aan ka jawaabin daawooyinka kale. Daaweynta cudurka loo yaqaano clinically isolated syndrome (CIS) oo ay ku jiraan interferons waxay yareyneysaa fursada in cudurka uu u gudbo MS. Waxtarka interferons iyo glatiramer acetate ee caruurta waxaa lagu qiyaasay in uu la mid yahay kan dadka waaweyn. Doorka qaar ka mid ah dawooyinka cusub sida fingolimod, teriflunomide, iyo dimethyl fumarate, laga bilaabo 2011, weli si buuxda uma cadda. Laga bilaabo 2017, rituximab waxaa si ballaaran loogu isticmaalay daaweynta RRMS.  Su'aal: Waa maxay daawada interferon-ka ee ugu horreysa?
interferon beta-1a